Abraxis BioScience | Evaluate

September 09, 2013

Abraxane gives contingent value approach a new lease of life

August 28, 2013

Event – Abraxane’s blockbuster potential in the lap of the FDA

November 13, 2012

Therapeutic focus – Abraxane pancreatic hit threatens to raise bar for competitors

October 15, 2012

Limited Abraxane approval shows wisdom of contingent value approach

September 04, 2012

Event – Celgene’s Abraxane looks for lung cancer approval

April 21, 2011

Celgene poised to shake off Revlimid safety blues

September 10, 2010

Therapeutic focus - Melanoma awaiting breakthrough but data approaching

July 02, 2010

Rumoured $20bn Sanofi-Aventis swoop could be about diversification

June 30, 2010

Celgene buys Abraxis for $2.9bn but insists premium is earned

April 16, 2010

Abraxis potential sale could hinge on valuation

March 31, 2010

Therapeutic focus - Late stage set backs sharpen focus on earlier lung cancer candidates

Load More